These findings are consistent with an age-dependent disruption of the beneficial adiponectin-AMPK-FOXO- and insulin-signaling pathways that apparently protected younger CHIP−/−-livers from NAFLD/NASH. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.